Terns Pharmaceuticals, Inc. Cost of Revenue

Cost of Revenue of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending December 31, 2021 was $114 Thousand (a 6.54% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue decreased by -33.72%
  • Annual Cost of Revenue for 2021 was $512 Thousand (a 29.95% increase from previous year)
  • Annual Cost of Revenue for 2020 was $394 Thousand (a 102.05% increase from previous year)
  • Annual Cost of Revenue for 2019 was $195 Thousand (a 200.0% increase from previous year)
  • Twelve month Cost of Revenue ending December 31, 2021 was $512 Thousand (a 1.59% increase compared to previous quarter)
  • Twelve month trailing Cost of Revenue increased by 10.11% year-over-year
Trailing Cost of Revenue for the last four month:
31 Dec '21 30 Sep '21 30 Jun '21 31 Mar '21
$512 Thousand $504 Thousand $496 Thousand $465 Thousand
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of Terns Pharmaceuticals, Inc.

Most recent Cost of Revenueof TERN including historical data for past 10 years.

Interactive Chart of Cost of Revenue of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.11 $0.11 $0.12 $0.17 $0.51
2020 $0.11 $0.1 $0.09 $0.39
2019 $0.07 $0.2
2018 $0.07

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.